Core Insights - Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on developing medicines for serious diseases, including eye diseases, cancer, and allergic conditions, competing with major players like Amgen and Biogen [1] Group 1: Stock Performance - Cowen & Co. reiterated its "Buy" rating for Regeneron, with the stock priced at $764.11, suggesting confidence in the company's future performance [2] - The stock price has seen a slight increase, currently at $768.64, up by approximately 1.15% from the previous session, indicating positive market sentiment [4] - Regeneron's market capitalization stands at approximately $79.86 billion, reflecting its significant presence in the biotechnology industry [5] Group 2: Company Events - Regeneron participated in the TD Cowen 46th Annual Health Care Conference, showcasing its latest developments and strategies to key players and stakeholders [3] - The trading volume for the day is 132,758 shares, indicating active investor interest [5]